2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras
  5. Ras Inhibitor

Ras Inhibitor

Ras Isoform Comparison

Ras Inhibitors (431):

Cat. No. Product Name Effect Purity
  • HY-143588
    KRAS G12C inhibitor 35
    		Inhibitor
    KRAS G12C inhibitor 35 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 35 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent CN112920183A, compound 3).
  • HY-153944
    KRAS G12C inhibitor 60
    		Inhibitor
    KRAS G12C inhibitor 60 (compound 23) is a Kras-G12C inhibitor. KRAS G12C inhibitor 60 can be used for the research of lung cancer, colorectal cancer, pancreatic cancer.
  • HY-P1382
    Rac1 Inhibitor W56
    		Inhibitor
    Rac1 Inhibitor W56 is a peptide containing residues 45-60 of Rac1. Rac1 Inhibitor W56 inhibits Rac1 interaction with guanine nucleotide exchange factors TrioN, GEF-H1, and Tiam.
  • HY-142481
    KRAS G12C inhibitor 30
    		Inhibitor
    KRAS G12C inhibitor 30 is a KRAS G12C inhibitor extracted from patent WO2021252339A1, compound 2. KRAS G12C inhibitor 30 can be used for the research of cancer.
  • HY-163582
    PROTAC SOS1 degrader-7
    		Inhibitor
    PROTAC SOS1 degrader-7 (Example 15) is a SOS1 PROTAC degrader. PROTAC SOS1 degrader-7 has anti-tumor activity . (Pink: SOS1 ligand (HY-163583); Black: linker (HY-163584); Blue: E3 ligase ligand (HY-W454906)).
  • HY-112494
    KRas G12C inhibitor 4
    		Inhibitor
    KRas G12C inhibitor 1 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
  • HY-144965
    SOS1-IN-12
    		Inhibitor
    SOS1-IN-12 is a potent son of sevenless homolog 1 (SOS1) inhibitor with a Ki of 0.11 nM for SOS1 and an IC50 of 47 nM for pERK. SOS1-IN-13 can be used for researching anticancer.
  • HY-168716
    SOS1-IN-17
    		Inhibitor
    SOS1-IN-17 (Compound 8d) is an orally active inhibitor for SOS1-KRASG12C interaction with an IC50 of 5.1 nM. SOS1-IN-17 inhibits ERK phosphorylation in DLD-1 cell with an IC50 of 18 nM. SOS1-IN-17 exhibits anti-proliferative activity in KRASG12C mutated Mia-Paca-2 cell with an IC50 of 0.11 μM. SOS1-IN-17 exhibits antitumor efficacy against pancreatic cancer in mouse model.
  • HY-161450
    LHF418
    		Inhibitor
    LHF418 is an effective SOS1 PROTAC degrader with a DC50 value of 209.4 nM in A549 cells. LHF418 can effectively inhibit RAS signaling and colony formation in KRAS-driven cancer cells. (Structural note: (Blue: Cereblon ligand (HY-A0003), Black: linker; Pink: SOS1 binder SOS1 Ligand intermediate-3 (HY-161452)).
  • HY-156363
    K-Ras-IN-2
    		Inhibitor
    K-Ras-IN-2 (Compound CHI-000-667) is a K-Ras antagonist, and can be used for tumor research.
  • HY-144213
    SOS1-IN-10
    		Inhibitor
    SOS1-IN-10 is a potent SOS1 inhibitor with an IC50 of 13 nM for KRAS G12C-SOS1 (WO2022017519A1, compound 8).
  • HY-131598C
    6-Thio-GTP tetrasodium
    		Inhibitor
    6-Thio-GTP (tetrasodium) is a Vav1-Rac inhibitor. 6-Thio-GTP (tetrasodium) inhibits TCR-stimulated T cell proliferation and CD28-mediated T cell survival. 6-Thio-GTP (tetrasodium) has an immunosuppressive effect in a mouse cardiac allograft transplant model and prolongs cardiac allograft survival.
  • HY-168012
    Pan-RAS-IN-6
    		Inhibitor
    Pan-RAS-IN-6 (compound 24) is an inhibitor targeting DUSP6, which reduces MAPK activation in the brain of the NCI-H1373-Luc model (DUSP6), at the same time, it shows significant tumor growth inhibition and tumor regression effects in the NSCLC brain metastasis mouse model. Pan-RAS-IN-6 shows high selectivity and strong inhibitory effects, especially in KRAS mutation-related signaling pathways, demonstrating varying inhibitory activity against different KRAS mutants and interacting proteins. The IC50 values for KRAS G12C, G12D, and G12V are 1.3 nM, 4.7 nM, and 0.3 nM, respectively.
  • HY-143359
    COTI-219
    		Inhibitor
    COTI-219 is an orally active inhibitor of KRAS. COTI-219 has antitumor activity.
  • HY-146061
    KRAS G12C inhibitor 48
    		Inhibitor
    KRAS G12C inhibitor 48 (compound 6e) is a potent KRAS G12C inhibitor with an IC50 of 639.91 nM. KRAS G12C inhibitor 48 (0-50 µM) shows anti-proliferative activity with IC50s of 0.796, 6.33, 16.14 µM for H358, H23, A549 cells, respectively.
  • HY-153899
    KRAS G12C inhibitor 59
    		Inhibitor
    KRAS G12C inhibitor 59 is a KRAS G12C inhibitor with anticancer effects (WO2023036282A1, compound II).
  • HY-145020
    KRAS G12C inhibitor 23
    		Inhibitor
    KRAS G12C inhibitor 23 is a KRAS G12C inhibitor. KRAS G12C inhibitor 23 inhibits H358 cells with an IC50 of 491 nM (WO2021218939A1, compound 1).
  • HY-172237
    Sosimerasib
    		Inhibitor
    Sosimerasib is the inhibitor for kirsten rat sarcoma viral oncogene homolog (KRAS) and exhibits antineoplastic activity.
  • HY-145022
    KRAS G12C inhibitor 25
    		Inhibitor
    KRAS G12C inhibitor 25 is a KRAS G12C inhibitor. KRAS G12C inhibitor 25 inhibits SOSl-assisted GDP/GTP exchanging activity of KRAS-G12C mutant (IC50=0.48 nM). From WO2021216770A1 compound 3.
  • HY-164493
    KRASG12C IN-13
    		Inhibitor
    KRASG12C IN-13 (LY3499446) is a potent KRAS G12C inhibitor. KRASG12C IN-13 is promising for research of advanced solid tumors including non-small cell lung cancer and colorectal cancer.